FO041URINARY PROTEOMICS MAY UNMASK THE RENAL POTENTIAL OF THE DPP-4 INHIBITOR LINAGLIPTIN IN PATIENTS WITH DIABETIC KIDNEY DISEASE. (18th May 2018)